细胞治疗临床研究和转化应用的思考

梅恒; 胡豫

doi:10.13201/j.issn.1004-2806.2019.07.001

细胞治疗临床研究和转化应用的思考

梅恒^1,2,
胡豫^1,2, ,

- 1. 华中科技大学同济医学院附属协和医院血液病研究所(武汉, 430022);
- 2. 湖北省肿瘤疾病细胞治疗临床医学研究中心

详细信息

通讯作者: 胡豫,E-mail:dr_huyu@126.com

中图分类号: R55

收稿日期: 2019-06-11

Consideration on clinical research and translational application of cell therapy

MEI Heng^1,2,
HU Yu^1,2, ,

More Information

Corresponding author: HU Yu, E-mail: dr_huyu@126.com

Received Date: 11 June 2019

摘要

- 细胞治疗 /
- 临床研究 /
- 转化应用
- cell therapy /
- clinical research /
- translational application

HTML全文

参考文献(11)

[1]	Maus MV, Grupp SA, Porter DL, et al.Antibody-modified T cells:CARs take the front seat for hematologic malignancies[J].Blood, 2014, 123:2625-2635.
[2]	Park JH, Geyer MB, Brentjens RJ.CD19-targeted CAR T-cell therapeutics for hematologic malignancies:interpreting clinical outcomes to date[J].Blood, 2016, 127:3312-3320.
[3]	Liu B, Song Y, Liu D.Clinical trials of CAR-T cells in China[J].J Hematol Oncol, 2017, 10:166.
[4]	中国国家卫生健康委办公厅.《关于征求体细胞治疗临床研究和转化应用管理办法(试行)(征求意见稿)意见的函》.2019-03-29.
[5]	Cyranoski D.Chinese hospitals set to sell experimental cell therapies[J].Nature, 2019, 569:170-171.
[6]	CDE.《关于细胞制品研究与评价技术指导原则(征求意见稿)》的通知.2016-12-19.
[7]	中国医药生物技术协会.《嵌合抗原受体修饰T细胞(CAR-T细胞)制剂制备质量管理规范》.2018-09.
[8]	Locke FL, Ghobadi A, Jacobson CA, et al.Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1):a single-arm, multicentre, phase 1-2 trial[J].Lancet Oncol, 2019, 20:31-42.
[9]	Guillerey C, Huntington ND, Smyth MJ.Targeting natural killer cells in cancer immunotherapy[J].Nat Immunol, 2016, 17:1025-1036.
[10]	Siegers GM, Lamb LS Jr.Cytotoxic and regulatory properties of circulating Vδ1+γδ T cells:a newplayer on the cell therapy field?[J].Mol Ther, 2014, 22:1416-1422.
[11]	Mirzaei HR, Mirzaei H, Lee SY, et al.Prospects for chimeric antigen receptor (CAR) gammadelta T cells:A potential game changer for adoptive T cell cancer immunotherapy[J].Cancer Lett, 2016, 380:413-423.